Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna’s mNexspike
Sanofi’s protein-based vaccine Nuvaxovid has demonstrated superior tolerability compared to Moderna’s next-generation messenger RNA vaccine, mNexspike, in a recent head-to-head trial. This finding is significant as it highlights the ongoing competition between traditional protein-based vaccines and newer mRNA technologies in the COVID-19 vaccine landscape. The context of this trial is critical, given the increasing scrutiny…









